Last updated: July 8, 2026
Liquidia Technologies, Inc. brought case 1:24-cv-02428 against the U.S. Food and Drug Administration (FDA). The matter concerns FDA regulatory action affecting Liquidia’s drug development and/or approval pathway, and is framed as a challenge under the federal judicial review of agency action. The case is pending and has not reached a merits decision in the public docket excerpt available in this response. No settlement, final judgment, or injunction outcome is available in the record content that can be cited here.
What is Liquidia Technologies, Inc. v. FDA 1:24-cv-02428 about?
Answer: A federal lawsuit seeking judicial review of an FDA decision or regulatory posture affecting Liquidia’s product pathway, typically where Liquidia alleges the FDA’s action is unlawful under the Administrative Procedure Act (APA) or related statutory standards.
What triggers these Liquidia-style FDA challenges?
Federal plaintiffs challenging FDA actions in matters like this usually focus on one or more of the following:
- FDA’s interpretation of statutory/ regulatory standards tied to approval, labeling, or review timelines
- FDA’s application of bioavailability/bioequivalence, clinical adequacy, or chemistry manufacturing and controls (CMC) requirements
- FDA’s handling of specific review obligations (for example, completeness, refusal to accept, or de facto denial scenarios)
- Agency failure to comply with required procedures (notice-and-comment, response to submissions, or adherence to review regulations)
How to read the case caption and docket number
- Court: U.S. District Court (federal district docket indicated by “1:24-cv-02428”)
- Case number: 1:24-cv-02428
- Parties: Liquidia Technologies, Inc. (plaintiff) vs. FDA (defendant)
What claims and legal theories are typically asserted in FDA suits like 1:24-cv-02428?
Answer: The complaint generally asserts that FDA’s challenged action is arbitrary, capricious, unlawful, or procedurally defective, most often under the APA and related statutory review standards.
Common APA frameworks in FDA litigation
In disputes of this type, plaintiffs typically argue:
- the FDA action lacked substantial evidence or relied on incorrect legal standards
- the agency failed to consider relevant evidence or provided inadequate explanation
- FDA acted inconsistently with governing regulations or prior guidance
Remedies usually sought
Such lawsuits often request:
- declaratory relief
- vacatur or remand to FDA for further action
- injunctive relief to stop implementation of the challenged decision
- court orders requiring FDA to take a specific next step within defined timeframes
What is the procedural posture in 1:24-cv-02428?
Answer: The case is pending at the time of this response; no final merits outcome, injunction, or settlement is reflected in the available cited record content here.
Key docket milestones that determine risk level for R&D timelines
For business planning, the risk profile shifts based on:
- whether the court grants a temporary restraining order (TRO) or preliminary injunction (PI)
- whether the case is remanded to FDA
- whether briefing focuses on jurisdiction/standing vs. merits
- whether FDA files a motion to dismiss under Rule 12(b)(6) or for lack of jurisdiction
What does the litigation analysis imply for Liquidia’s development plan and regulatory timeline?
Answer: Pending FDA litigation creates program risk through delayed milestones, increased cost of regulatory strategy changes, and potential changes in the regulatory path the company must follow.
Business impact channels
- Schedule risk: Litigation can extend time to resolution of a submission or review issue.
- Regulatory strategy risk: A court finding against FDA can reshape the standards of evaluation applied by the agency on remand.
- IP and exclusivity spillovers: If the case affects an approval date or labeling outcome, it can change downstream exclusivity timing and generic/biosimilar leverage.
- Resource allocation: Legal costs and regulatory rework can divert resources from parallel clinical or CMC activities.
How strong is Liquidia’s likely position on the merits?
Answer: No merits analysis is supportable from the limited docket content available in this response. A correct strength assessment requires identifying the specific FDA action challenged, the administrative record, and the complaint’s asserted statutory and APA grounds.
What outcomes matter most to investors, licensors, and generic competitors?
Answer: The highest-value outcomes are those that either (a) force FDA to re-evaluate or redo the review under corrected legal standards, or (b) sustain FDA’s action and narrow Liquidia’s ability to re-approach the same regulatory hurdle quickly.
Decision tree: practical scenarios
- If remand is ordered: program timelines may reset; labeling and approval constraints can be altered.
- If FDA action is upheld: Liquidia may need a new submission, additional clinical evidence, or different formulation/product design.
- If injunctive relief is granted: it can prevent implementation of a denial or other adverse step and accelerate reconsideration.
Are there any patent, Orange Book, or Paragraph IV implications in this specific case?
Answer: This case, as framed by the available docket content, appears to be a direct challenge to FDA regulatory action rather than patent litigation under Hatch-Waxman/§ 505(b)(2) or Paragraph IV certifications. Patent-specific impacts depend on whether the FDA action affects an ANDA/BLA, exclusivity determinations, or labeling.
What to verify for downstream Hatch-Waxman risk
For generics and branded competitors, the relevant litigation hooks are usually:
- whether the FDA action alters approval timing for a listed drug
- whether a new approval or labeling change triggers new exclusivity categories
- whether the drug is protected by unexpired Orange Book patents and how FDA’s action influences the regulatory listing status
Key Takeaways
- Case: Liquidia Technologies, Inc. v. FDA, 1:24-cv-02428.
- Core purpose: Judicial review of an FDA regulatory decision or posture affecting Liquidia’s product pathway.
- Current status: Pending; no final merits disposition or settlement outcome is reflected in the limited cited docket content available here.
- Business consequence: Schedule, regulatory strategy, and downstream competitive positioning can shift depending on whether the court orders remand or grants injunctive relief.
FAQs
1) What court has jurisdiction over 1:24-cv-02428?
Federal district court jurisdiction is indicated by the docket format, but the specific district and judge are not included in the available cited record content here.
2) Does 1:24-cv-02428 involve Hatch-Waxman Paragraph IV litigation?
The available record content indicates an FDA regulatory challenge rather than a patent dispute under the Hatch-Waxman framework, but patent-certificate-specific effects would depend on the underlying FDA action.
3) Can a remand from this case change approval timelines?
Yes. If the court orders remand with instructions, FDA must reconsider the challenged decision under the court’s legal framework, which can reset or accelerate review steps.
4) What remedies do plaintiffs typically request in FDA APA suits?
Common remedies include declaratory relief, vacatur/remand, and in some cases preliminary injunctive relief.
5) Who is likely affected besides Liquidia?
Any stakeholder whose business depends on the same FDA decision, including licensing partners, clinical collaborators, and competitors monitoring approval timing.
References
- FDA public docket entry for Liquidia Technologies, Inc. v. U.S. Food and Drug Administration, 1:24-cv-02428 (accessed via the docket content available to this response).
- U.S. Food and Drug Administration. Administrative Procedure Act review standards (general legal framework) as reflected in FDA litigation practice.
